CERo Therapeutics (CERO) Competitors $8.30 0.00 (0.00%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$8.26 -0.04 (-0.48%) As of 08/22/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CERO vs. ERNA, FLGC, IMCC, PRPH, CARM, CSCI, GOVX, PHXM, LGVN, and HOOKShould you be buying CERo Therapeutics stock or one of its competitors? The main competitors of CERo Therapeutics include Ernexa Therapeutics (ERNA), Flora Growth (FLGC), IM Cannabis (IMCC), ProPhase Labs (PRPH), Carisma Therapeutics (CARM), COSCIENS Biopharma (CSCI), GeoVax Labs (GOVX), PHAXIAM Therapeutics (PHXM), Longeveron (LGVN), and HOOKIPA Pharma (HOOK). These companies are all part of the "pharmaceutical products" industry. CERo Therapeutics vs. Its Competitors Ernexa Therapeutics Flora Growth IM Cannabis ProPhase Labs Carisma Therapeutics COSCIENS Biopharma GeoVax Labs PHAXIAM Therapeutics Longeveron HOOKIPA Pharma Ernexa Therapeutics (NASDAQ:ERNA) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability. Which has more risk and volatility, ERNA or CERO? Ernexa Therapeutics has a beta of 5.42, indicating that its stock price is 442% more volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Does the media favor ERNA or CERO? In the previous week, CERo Therapeutics had 1 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 1 mentions for CERo Therapeutics and 0 mentions for Ernexa Therapeutics. CERo Therapeutics' average media sentiment score of 1.38 beat Ernexa Therapeutics' score of -0.68 indicating that CERo Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Ernexa Therapeutics Negative CERo Therapeutics Positive Do analysts rate ERNA or CERO? CERo Therapeutics has a consensus target price of $45.00, suggesting a potential upside of 442.17%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than Ernexa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ernexa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00CERo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has preferable valuation and earnings, ERNA or CERO? CERo Therapeutics has lower revenue, but higher earnings than Ernexa Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErnexa Therapeutics$580K19.84-$44.54M-$8.31-0.18CERo TherapeuticsN/AN/A-$8.30MN/AN/A Do insiders & institutionals believe in ERNA or CERO? 70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are held by institutional investors. 1.5% of Ernexa Therapeutics shares are held by insiders. Comparatively, 12.7% of CERo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is ERNA or CERO more profitable? CERo Therapeutics has a net margin of 0.00% compared to Ernexa Therapeutics' net margin of -7,652.75%. Company Net Margins Return on Equity Return on Assets Ernexa Therapeutics-7,652.75% N/A -682.08% CERo Therapeutics N/A N/A -199.71% SummaryCERo Therapeutics beats Ernexa Therapeutics on 10 of the 13 factors compared between the two stocks. Get CERo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CERO vs. The Competition Export to ExcelMetricCERo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.21M$2.54B$5.75B$9.62BDividend YieldN/A1.57%4.40%4.10%P/E RatioN/A22.9131.3026.05Price / SalesN/A554.08432.98193.75Price / CashN/A180.4637.7358.48Price / Book-0.205.939.536.61Net Income-$8.30M$31.83M$3.26B$265.65M7 Day Performance3.75%1.89%2.13%2.02%1 Month Performance0.85%1.33%2.80%-0.31%1 Year Performance-97.02%8.84%30.68%19.06% CERo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CEROCERo Therapeutics3.4673 of 5 stars$8.30flat$45.00+442.2%-97.1%$3.21MN/A0.008Positive NewsEarnings ReportERNAErnexa Therapeutics0.3855 of 5 stars$1.69+4.3%N/A-94.7%$11.93M$580K0.0010Short Interest ↑FLGCFlora Growth3.3035 of 5 stars$18.21-11.6%$93.00+410.7%-44.7%$11.90M$59.51M0.00280IMCCIM Cannabis0.4914 of 5 stars$2.60-11.3%N/A-20.7%$11.85M$39.44M0.00340PRPHProPhase Labs1.2369 of 5 stars$0.35+25.7%N/A-88.2%$11.70M$6.77M-0.28130High Trading VolumeCARMCarisma Therapeutics2.9892 of 5 stars$0.28+1.6%$1.93+587.5%-80.2%$11.51M$19.63M0.0020News CoverageShort Interest ↓CSCICOSCIENS BiopharmaN/A$3.56-0.6%N/AN/A$11.26M$9.59M0.0020Positive NewsGOVXGeoVax Labs1.8482 of 5 stars$0.70+2.8%$8.88+1,169.7%-89.5%$10.83M$3.95M0.0010Short Interest ↑Gap UpPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049LGVNLongeveron3.5406 of 5 stars$0.68-2.1%$8.67+1,173.6%-69.6%$10.55M$2.39M0.0020HOOKHOOKIPA Pharma2.7741 of 5 stars$0.85+3.0%$4.50+432.5%-83.0%$10.30M$9.35M-0.14160 Related Companies and Tools Related Companies ERNA Alternatives FLGC Alternatives IMCC Alternatives PRPH Alternatives CARM Alternatives CSCI Alternatives GOVX Alternatives PHXM Alternatives LGVN Alternatives HOOK Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CERO) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CERo Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CERo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access